AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32673226 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 214
Study 35514022 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (maximum dose 40 mg/daily)
Number of subjects: 69
Study 35514022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 33478397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 supplementation (60,000 IU/week for 12 weeks)
Number of subjects: 140
Study 33478397 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D2 supplementation (20,000 IU/week for 12 weeks)
Number of subjects: 140
Study 33478397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 supplementation
Number of subjects: 140
Study 33478397 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D2 supplementation
Number of subjects: 140
Study 33148023 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis
Number of subjects: 24
Study 33148023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 32232434 — intervention group
Group type: EXPERIMENTAL
Intervention: Skilful Care Training Package (SCTP) delivered by physiotherapists to care staff
Number of subjects: 146
Study 32232434 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 146
Study 35258035 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab + risperidone
Number of subjects: 40
Study 35258035 — intervention group
Group type: COMPARATOR
Intervention: Placebo + risperidone
Number of subjects: 40
Study 32417993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib dose interruption
Number of subjects: 0
Study 32417993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib dose reduction
Number of subjects: 0
Study 32417993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib discontinuation
Number of subjects: 0
Study 32417993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AEs requiring dose adjustment)
Number of subjects: 0
Study 32417993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 0
Study 35754690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 50
Study 35754690 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitored exercise
Number of subjects: 50
Study 33682367 — intervention group
Group type: EXPERIMENTAL
Intervention: UL-Tea (3 doses/day of catechin-rich green tea)
Number of subjects: 12
Study 33682367 — intervention group
Group type: COMPARATOR
Intervention: UL-Placebo (placebo control)
Number of subjects: 12
Study 32859433 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 1509
Study 32859433 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 1509
Study 32552562 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive appeals highlighting microbiome benefits
Number of subjects: 298
Study 32552562 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal analysis, latent class analysis, and equilibrium values for transition matrices
Number of subjects: 298
Study 34342588 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive lung cancer screening model using electronic medical records and neural networks
Number of subjects: 1417711
Study 32208783 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMFA‐INDX model for GT1a
Number of subjects: 196
Study 32208783 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMSIA‐SEHA model for GT1a Y93H
Number of subjects: 196
Study 32208783 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMSIA‐SEHA model for GT1a L31V
Number of subjects: 196
Study 35475796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailing capsule (BLC)
Number of subjects: 0
Study 33097932 — intervention group
Group type: COMPARATOR
Intervention: Soy food intake 1 time/week
Number of subjects: 24622
Study 33097932 — intervention group
Group type: COMPARATOR
Intervention: Soy food intake 2-3 times/week
Number of subjects: 24622
Study 33097932 — intervention group
Group type: COMPARATOR
Intervention: Soy food intake ≥4 times/week
Number of subjects: 24622
Study 33097932 — intervention group
Group type: COMPARATOR
Intervention: Energy-adjusted soy food intake (grams per 1000 kilocalories) quartiles
Number of subjects: 24622
Study 35123483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 337
Study 35123483 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 337
Study 33140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge with sutures (SG)
Number of subjects: 36
Study 33140428 — intervention group
Group type: COMPARATOR
Intervention: Collagen sponge without sutures (nSG)
Number of subjects: 36
Study 35537570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-NSA prosthesis
Number of subjects: 50
Study 35537570 — intervention group
Group type: COMPARATOR
Intervention: Variable-NSA prosthesis
Number of subjects: 50
Study 33675460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4-mg)
Number of subjects: 13
Study 33675460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2-mg)
Number of subjects: 13
Study 33675460 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 13
Study 32129962 — intervention group
Group type: EXPERIMENTAL
Intervention: 650-microsecond, 1064-nm pulsed YAG laser
Number of subjects: 15
Study 32129962 — intervention group
Group type: COMPARATOR
Intervention: 308-nm excimer laser
Number of subjects: 15
Study 34117519 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 80
Study 34117519 — intervention group
Group type: COMPARATOR
Intervention: Reduced intensity conditioning (RIC)
Number of subjects: 80
Study 32379777 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment
Number of subjects: 914
Study 34696774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 3448
Study 34696774 — intervention group
Group type: COMPARATOR
Intervention: Liberal glucose control
Number of subjects: 3448
Study 32285479 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible ovarian follicles at the newborn visit (n=133)
Number of subjects: 163
Study 32285479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ovarian growth trajectory
Number of subjects: 163
Study 33974467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 3
Study 34939917 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training for primary care physicians
Number of subjects: 1138
Study 34939917 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training for the entire practice team
Number of subjects: 1138
Study 34939917 — intervention group
Group type: COMPARATOR
Intervention: Control group with general instructions about medication
Number of subjects: 1138
Study 34939917 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention (69 practices)
Number of subjects: 1138
Study 34939917 — intervention group
Group type: EXPERIMENTAL
Intervention: Team training (35 practices)
Number of subjects: 1138
Study 35345256 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous phosphocreatine (PCr)
Number of subjects: 105
Study 35345256 — intervention group
Group type: COMPARATOR
Intervention: Control (routine hydration therapy)
Number of subjects: 105
Study 33677189 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 16
Study 33916366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (100% energy intake on 5 non-restricted days, 25% on 2 restricted days)
Number of subjects: 98
Study 33916366 — intervention group
Group type: COMPARATOR
Intervention: Continuous Calorie Restriction (CCR) - daily energy intake of 80%
Number of subjects: 98
Study 33916366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR)
Number of subjects: 98
Study 35109140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TG-DHA supplementation (2,040 mg DHA daily for six months)
Number of subjects: 28
Study 32576901 — intervention group
Group type: COMPARATOR
Intervention: CTPA using the test bolus approach with 20 ml contrast agent at 100 kVp
Number of subjects: 70
Study 32576901 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPA using the biphasic time-enhancement curves approach with 10 ml contrast agent at 80 kVp
Number of subjects: 70
Study 32576901 — intervention group
Group type: COMPARATOR
Intervention: CTPA using the test bolus approach
Number of subjects: 70
Study 32576901 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPA using the optimized protocol
Number of subjects: 70
Study 35991062 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based casual video game training for 4 weeks
Number of subjects: 56
Study 35991062 — intervention group
Group type: COMPARATOR
Intervention: Daily life activities without any intervention (Control)
Number of subjects: 56
Study 32109215 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir Valganciklovir Teva® (VT group)
Number of subjects: 66
Study 32109215 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvanocyte® (A group)
Number of subjects: 66
Study 32109215 — intervention group
Group type: EXPERIMENTAL
Intervention: Valcyte® (V group)
Number of subjects: 66
Study 35171954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing a mixture of Boswellia serrata Roxb., chlorophyll, green tea extract, glucosamine, chondroitin sulfate, hyaluronic acid, and non-hydrolised type II collagen for 60 days
Number of subjects: 40
Study 35171954 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 40
Study 35221681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Active at Home (SAaH) training program
Number of subjects: 264
Study 35221681 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study 32605885 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative whole-wheat synbiotic pasta
Number of subjects: 41
Study 32605885 — intervention group
Group type: COMPARATOR
Intervention: Control whole-wheat pasta
Number of subjects: 41
Study 35709548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 international units)
Number of subjects: 200
Study 35709548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32939054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus cisplatin radiation (NCRT)
Number of subjects: 404
Study 32939054 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin radiation (CRT)
Number of subjects: 404
Study 33834490 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (clinical reasoning approach)
Number of subjects: 123176
Study 33834490 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (FRAT)
Number of subjects: 123176
Study 32146127 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular lymph node analysis using FXYD3
Number of subjects: 76
Study 35606829 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric antibiotics (ampicillin and gentamicin)
Number of subjects: 802
Study 35606829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 33038017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic treatment product
Number of subjects: 58
Study 33038017 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 58
Study 35428344 — intervention group
Group type: EXPERIMENTAL
Intervention: NET alone
Number of subjects: 22
Study 35428344 — intervention group
Group type: EXPERIMENTAL
Intervention: NET plus genealogical assessment
Number of subjects: 22
Study 35428344 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 33749826 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1799
Study 33749826 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1799
Study 32534361 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 125
Study 32534361 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 125
Study 36370634 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0
Study 36370634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34806679 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 0
Study 34806679 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study 35994847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diterpene ginkgolides meglumine injection (DGMI)
Number of subjects: 399
Study 35994847 — intervention group
Group type: COMPARATOR
Intervention: Ginaton
Number of subjects: 399
Study 33974964 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (n = 20)
Number of subjects: 60
Study 33974964 — intervention group
Group type: COMPARATOR
Intervention: SHAM (n = 20)
Number of subjects: 60
Study 33974964 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 60
Study 33974964 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 32571269 — intervention group
Group type: EXPERIMENTAL
Intervention: Resending the complete questionnaire to non-responders
Number of subjects: 1824
Study 32571269 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call to participants
Number of subjects: 1824
Study 35217440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg, subcutaneous every 8 weeks for 56 weeks
Number of subjects: 0
Study 35217440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg, subcutaneous every 8 weeks for 56 weeks
Number of subjects: 0
Study 35217440 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs, twice-daily for 56 weeks
Number of subjects: 0
Study 35217440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 0
Study 35217440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 0
Study 35217440 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 0
Study 32304415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin (0.4 µg/kg) + platelet transfusion (2 U)
Number of subjects: 140
Study 32304415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin + platelet transfusion
Number of subjects: 140
Study 35087624 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (CVD)
Number of subjects: 192
Study 35087624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 32453198 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole as part of multimodal therapy
Number of subjects: 55
Study 35326010 — intervention group
Group type: EXPERIMENTAL
Intervention: 28‐kHz frequency
Number of subjects: 207
Study 35326010 — intervention group
Group type: EXPERIMENTAL
Intervention: 42‐kHz frequency
Number of subjects: 207
Study 35326010 — intervention group
Group type: EXPERIMENTAL
Intervention: 53‐kHz frequency
Number of subjects: 207
Study 32271702 — intervention group
Group type: EXPERIMENTAL
Intervention: California's 2010 Healthy Beverages in Child Care Act adherence in 2016
Number of subjects: 680
Study 32271702 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk provision adherence
Number of subjects: 680
Study 32271702 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% juice provision adherence
Number of subjects: 680
Study 32271702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages provision adherence
Number of subjects: 680
Study 32271702 — intervention group
Group type: COMPARATOR
Intervention: Adherence comparison between centers and homes
Number of subjects: 680
Study 32271702 — intervention group
Group type: COMPARATOR
Intervention: Adherence comparison between CACFP and non-CACFP sites
Number of subjects: 680
Study 34315481 — intervention group
Group type: EXPERIMENTAL
Intervention: GLAs with demonstrated cardiovascular benefit (e.g., glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors)
Number of subjects: 9823
Study 34315481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CAPTURE sample
Number of subjects: 9823
Study 36219998 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (8 sessions over 4 weeks)
Number of subjects: 84
Study 36219998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 33429735 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (Octagam 10%) 2 g/kg every 4 weeks until week 16
Number of subjects: 0
Study 33429735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33429735 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (Octagam 10%) 2 g/kg every 4 weeks for 24 weeks (open-label Extension Period)
Number of subjects: 0
Study 32428937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active serum and mask
Number of subjects: 30
Study 32428937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35748112 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback, an online unguided self‐help program
Number of subjects: 0
Study 35748112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat or e‐mail support from a recovered expert patient
Number of subjects: 0
Study 35748112 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with expert‐patient support
Number of subjects: 0
Study 35748112 — intervention group
Group type: COMPARATOR
Intervention: Care‐as‐usual
Number of subjects: 0
Study 32722939 — intervention group
Group type: EXPERIMENTAL
Intervention: O3FAs/PPs group: Oral omega-3 fatty acids (O3FAs) two capsules twice daily (total daily dose of 1040 mg/day) for 6 months with punctal plugs.
Number of subjects: 90
Study 32722939 — intervention group
Group type: EXPERIMENTAL
Intervention: PPs group: Punctal plugs with oral placebo.
Number of subjects: 90
Study 32722939 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin group: No intervention.
Number of subjects: 90
Study 34299917 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare PLAY policy implemented for eight weeks
Number of subjects: 148
Study 34299917 — intervention group
Group type: COMPARATOR
Intervention: Control group continued typical daily routines
Number of subjects: 148
Study 33246931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 1096
Study 33246931 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 1096
Study 35218145 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural social facilitation treatment (FBSFT)
Number of subjects: 114
Study 35218145 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114
Study 36108881 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row repair with horizontal LHBT augmentation
Number of subjects: 18
Study 36108881 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row repair with v-shaped LHBT augmentation
Number of subjects: 18
Study 36108881 — intervention group
Group type: COMPARATOR
Intervention: Traditional single-row repair
Number of subjects: 18
Study 32589321 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyronie patients with low testosterone levels
Number of subjects: 284
Study 32589321 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 284
Study 32589321 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyronie patients
Number of subjects: 284
Study 35466521 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. amoxicillin for 7 days
Number of subjects: 119
Study 35466521 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. amoxicillin for 10 days
Number of subjects: 119
Study 35466521 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. amoxicillin for 7 days
Number of subjects: 119
Study 35466521 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. amoxicillin for 10 days
Number of subjects: 119
Study 34412189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A teaching group
Number of subjects: 70
Study 32469881 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cast position
Number of subjects: 105
Study 32469881 — intervention group
Group type: COMPARATOR
Intervention: Volar-flexion and ulnar deviation cast
Number of subjects: 105
Study 35081747 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab prior to or in combination with TACE
Number of subjects: 0
Study 35081747 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32900913 — intervention group
Group type: COMPARATOR
Intervention: Ventilator settings (including ventilatory modes, triggering sensitivity, inspiratory pressurization, and inspiratory cycling-off)
Number of subjects: 0
Study 32900913 — intervention group
Group type: COMPARATOR
Intervention: Differences in pleural pressure levels between the nondependent (ND) and dependent (D) regions
Number of subjects: 0
Study 32900913 — intervention group
Group type: COMPARATOR
Intervention: Lung mechanics between the ND and D regions
Number of subjects: 0
Study 32900913 — intervention group
Group type: COMPARATOR
Intervention: Gas flow from the D region to the ND region
Number of subjects: 0
Study 35832028 — intervention group
Group type: EXPERIMENTAL
Intervention: Date seed powder (DSP, n=18)
Number of subjects: 36
Study 35832028 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran powder (placebo, n=18)
Number of subjects: 36
Study 33798298 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's three-needle therapy and motor relearning regimen
Number of subjects: 60
Study 33798298 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation regimen (Control)
Number of subjects: 60
Study 34763959 — intervention group
Group type: EXPERIMENTAL
Intervention: Affordable Care Act (ACA) removal of cost sharing for colorectal cancer screening
Number of subjects: 2113283
Study 34763959 — intervention group
Group type: COMPARATOR
Intervention: Pre-ACA zero cost sharing for colorectal cancer screening
Number of subjects: 2113283
Study 33188155 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 105